TOWA PHARMACEUTICAL CO.,LTD. [4553.T]
TOKYO, May 21 (Pulse News Wire) – Towa Pharmaceutical CO.,LTD. (4553.T) announced its board appointments following today's board meeting.
The appointments will take effect pending approval at the upcoming annual shareholders' meeting scheduled for June 24, 2026. Key appointments include: - Yoshida Itsuro, reappointed as President and CEO. - Nakamura Hideo, newly appointed as Executive Director and Head of the Corporate Office. - Taniguchi Muneya, newly appointed as an external director and audit committee member. Additionally, existing directors Uchikawa Osamu, Kokubun Toshikazu, Takeyasu Masahiro, and Honoki Norikazu were also reappointed.
Notably, Honoki Norikazu remains designated as an independent director according to Tokyo Stock Exchange criteria. Newly appointed Taniguchi Muneya brings extensive experience from Mitsubishi UFJ Financial Group, serving in various executive roles until his appointment as Special Advisor at Mitsubishi UFJ Securities Holdings Co., Ltd. in April 2025. He currently holds positions at Nichicon Corporation and several non-profit organizations. The company plans to continue designating Honoki Norikazu and Oishi Kaori, along with newly appointed Taniguchi Muneya, as independent directors subject to shareholder approval.
🟡 Confidence: Standard AI-translated content.